Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Retrospective, Observational Study to Evaluate Clinical and Economic Outcomes of Patients With MRSA Hospital-Acquired Pneumonia Treated With Linezolid Or Vancomycin.

Next Previous
Trial Profile

Multicenter, Retrospective, Observational Study to Evaluate Clinical and Economic Outcomes of Patients With MRSA Hospital-Acquired Pneumonia Treated With Linezolid Or Vancomycin.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linezolid (Primary) ; Vancomycin (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections; Ventilator associated pneumonia
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 08 Jul 2013 Planned end date changed from 1 Jan 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
  • 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 25 Feb 2013 Primary emdpoint amended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top